Ted W. Love, M.D. joined Onyx in January 2010 as Executive Vice President and Head of Research and Development. In January 2011 he assumed responsibility for technical operations. Prior to joining Onyx, Ted was President, Chief Executive Officer and Chairman of the Board of Directors at Nuvelo, which he joined in 2001. Previously, he served as Senior Vice President of Development at Theravance, Inc. Earlier in his career; Ted spent six years at Genentech, Inc. in a number of senior management positions in Medical Affairs and Product Development. As Vice President of Product Development and Regulatory Affairs at Genentech, he oversaw all drugs in development including Herceptin, Rituxan, and TNKase. He also served as Chairman of Genentech’s Product Development Committee. Ted earned his undergraduate degree in molecular biology from Haverford College and his medical degree at Yale Medical School. He completed his residency and fellowship training in internal medicine and cardiology at Harvard Medical School and Massachusetts General Hospital, where he later served on the faculty. Ted currently serves on the Board of Directors of Bio-Rad Laboratories, Inc., Affymax, Inc., Santarus, Inc., ARCA biopharma, Inc., and on the California Institute for Regenerative Medicine (CIRM) Independent Citizens’ Oversight Committee. He is a member of the 2002 Class of Henry Crown Fellows and the Aspen Global Leadership Network at the Aspen Institute.